SCHOTT Pharma rises after J.P. Morgan initiates with 'Overweight'

SCHOTT Pharma AG & Co. KGaA

15/09/2026 07:48

** Shares in German medical equipment supplier SCHOTT Pharma 1SXP.DE rise 4.6% in early-Frankfurt trade after J.P. Morgan initiates coverage with "Overweight", seeing growth upside
** Broker says "headwinds are largely behind" the company and sees a rebound to +12% EPS growth in FY27
** Broker forecasts EBITDA and EPS growth CAGRs of 10.4% and 13.6% over 2026-2029, respectively
** Brokerage says margin gains should come from a shift toward higher-value products and better use of existing capacity, especially in prefillable syringes
** JPM says valuation remains attractive versus medtech peers, adding risks to estimates are to the upside
** Out of 13 analysts that cover SCHOTT Pharma AG & Co. KGaA, 10 rate the stock "strong buy" or "buy,"​ two rate "hold" and one rates the stock "sell" — LSEG data

(Reporting by Basile Day)
((Basile.day@thomsonreuters.com))